Medication info
Linarutine Duo Extended-Release Tablets 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Linarutine Duo Extended-Release Tablets 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Oval extended-release tablet that is white to almost white with 'S251' engraved on one side
Packaging
28 tablets/box (7 tablets/PTP x 4)
Approval status
Active

MFDS item code 202400629 · Approved 2024.03.22 · Insurance code 648508270

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride, as extended-release, 2000 mg. This medicine should be taken with food once daily, preferably with the evening meal. For this medicine 5/1000 mg extended-release tablets, take 1 tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication combines linagliptin and metformin, prescribed to assist patients with type 2 diabetes in controlling blood sugar levels. Taken alongside dietary adjustments and exercise therapy, it effectively helps manage blood sugar levels. This contributes to more stable blood sugar management, promoting a healthier life.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride, as extended-release, 2000 mg. This medicine should be taken with food once daily, preferably with the evening meal. For this medicine 5/1000 mg extended-release tablets, take 1 tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication consists of two components that aid in blood sugar control. Firstly, one component of this medication can rarely cause a serious condition known as lactic acidosis. Lactic acidosis is a dangerous condition that occurs when there is excessive lactic acid buildup in the body, which can be life-threatening if untreated. Therefore, it should not be used in patients with certain conditions or severely impaired kidney function. This includes patients with type 1 diabetes, severe renal impairment, acute myocardial infarction, and liver dysfunction. Additionally, this medication should be avoided in cases of acute conditions such as dehydration, severe infection, severe trauma, and shock. While taking this medication, hypoglycemia may occur, so caution is needed, especially when used with insulin or sulfonylureas, and dosage adjustments may be required as necessary. To reduce the risk of lactic acidosis, kidney function should be regularly monitored, and if kidney function declines, this medication should be discontinued. When iodine-based contrast agents are used during surgeries or radiologic tests, this medication should be discontinued for a certain period before and after the examination, and can be resumed after kidney function is restored. This medication can cause gastrointestinal disturbances, abdominal pain, diarrhea, nausea, and vomiting, most of which improve naturally over time. Rarely, acute pancreatitis or blistering skin diseases may occur, so if severe abdominal pain or blisters on the skin develop, contact a doctor immediately. Long-term use may carry a risk of vitamin B12 deficiency, thus when experiencing anemia or neurological symptoms, vitamin B12 levels should be checked and supplemented if necessary. This medication must be swallowed whole, without crushing or chewing the tablets, and it's normal for some tablet shells to appear in the stool. Women who are pregnant or breastfeeding are advised to avoid using this medication, and if planning to become pregnant, should consult with a doctor. Elderly patients are often at risk of reduced kidney function, so regular kidney function checks are advised, and it is preferable to start at the lowest effective dose. Finally, this medication may interact with various other drugs, so it is essential to inform a doctor or pharmacist of any other medications being taken.

Side effects

Severe lactic acidosis, hypoglycemia, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemia, dysgeusia, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, pemphigoid-like eruption, severe joint pain with disability, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reaction, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, rib fracture, hand fracture, chest discomfort, asthenia, pain, epistaxis, oropharyngeal pain, voice disorder, allergic rhinitis, exertional dyspnea, wet cough, rhinorrhea, pulmonary mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, male pattern baldness, hyperhidrosis, hair loss, dermatitis, goiter, confusion state, nocturia, dermatitis, hypertension, erectile dysfunction, dry eye, cataract, allergic conjunctivitis, vitreous hemorrhage, stomatitis, mediastinitis, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, anal bleeding, cheilitis, dental caries, enteritis, gastritis, dysphagia, gastric ulcer, gum bleeding, tooth loss, hemorrhoids, lower abdominal pain, viral upper respiratory infection, periodontitis, influenza, pharyngitis, rhinitis, upper respiratory infection, increased serum triglycerides, increased urine albumin/creatinine ratio, urine leukocyte positive, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase activity, ALT increase, increased serum triglycerides, insomnia, depression

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air or moisture from entering, maintaining a storage temperature between 1°C to 30°C at room temperature is important. Proper storage will help maintain the effectiveness of the drug for a longer period.

Appearance and packaging

Appearance

Oval extended-release tablet that is white to almost white with 'S251' engraved on one side

Package unit

28 tablets/box (7 tablets/PTP x 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.